News
A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...
The transaction, which sources say could be agreed upon as soon as Monday, would price SpringWorks at $47 per share, totaling ...
So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...
Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between ...
Scores of FDA employees are searching for an exit from an agency in turmoil, especially staffers tasked with reviewing drug ...
With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...
6hon MSN
Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.
Shares of Merck and Verizon are retreating Friday morning, sending the Dow Jones Industrial Average into negative territory.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results